Dentsply Sirona’s first quarter results reflected a company in the midst of operational transformation, with revenue holding steady year over year but outperforming Wall Street’s expectations. Management attributed the quarter’s performance to both ongoing restructuring efforts and investments in commercial capabilities, noting that early momentum is visible in customer engagement and new distribution partnerships. CEO Daniel T. Scavilla described the business as “in transition,” emphasizing that most benefits from these initiatives are yet to be realized, and acknowledging the ongoing impact of external market pressures and segment-specific headwinds.
Is now the time to buy XRAY? Find out in our full research report (it’s free for active Edge members).
Dentsply Sirona (XRAY) Q1 CY2026 Highlights:
- Revenue: $880 million vs analyst estimates of $839.4 million (flat year on year, 4.8% beat)
- Adjusted EPS: $0.27 vs analyst estimates of $0.27 (in line)
- Adjusted EBITDA: $129 million vs analyst estimates of $128.6 million (14.7% margin, in line)
- The company reconfirmed its revenue guidance for the full year of $3.55 billion at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $1.45 at the midpoint
- Operating Margin: -4%, down from 7.2% in the same quarter last year
- Constant Currency Revenue fell 6.7% year on year (-4.4% in the same quarter last year)
- Market Capitalization: $2.19 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Dentsply Sirona’s Q1 Earnings Call
- Allen Charles Lutz (Bank of America) asked about the timing of restructuring benefits. CEO Daniel T. Scavilla clarified that material improvements are expected mainly in the fourth quarter and more substantially in 2027 and 2028.
- Jeffrey D. Johnson (R.W. Baird) questioned the EDS segment’s decline. Scavilla attributed it to dealer destocking in Europe and specific market softness but believes it is a timing issue rather than a persistent structural problem.
- Michael Anthony Sarcone (Jefferies) sought clarity on gross margin contraction. Interim CFO Michael Pomeroy pointed to tariffs and inventory-related impacts, expecting at least 300 basis points of improvement by the third quarter as these headwinds lessen.
- Lilia-Celine Lozada (JPMorgan) asked about maintaining guidance despite the revenue beat. Scavilla stated he prefers a conservative approach and will revisit guidance after more quarters of execution.
- Steven James Valiquette (Mizuho Securities) inquired about competition in digital equipment. Scavilla acknowledged new low-cost entrants and said Dentsply Sirona will use bundled solutions and its broad portfolio to compete effectively.
Catalysts in Upcoming Quarters
Over the coming quarters, the StockStory team will focus on (1) the pace and impact of restructuring savings and how quickly they translate to margin improvement, (2) the adoption trajectory for new AI-enabled diagnostic products and broader digital portfolio uptake, and (3) the effectiveness of expanded distribution partnerships in driving U.S. and international market share gains. Progress in revitalizing core segments like implants and CAD/CAM will be additional key markers for the company’s turnaround.
Dentsply Sirona currently trades at $11.00, down from $11.37 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
